Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance
1. EW surpassed Q2 2025 revenue and earnings expectations with $1.53 billion sales. 2. Company raised full-year sales guidance to $5.90-$6.10 billion, exceeding consensus. 3. TAVR sales grew 8.9%, significantly contributing to overall revenue growth. 4. Analysts show increased confidence, raising price forecasts and maintaining buy ratings. 5. Stock rose 4.87%, reflecting positive market sentiment following earnings report.